Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 184.91M | 160.18M | 194.62M | 292.60M | 213.58M | 295.31M |
Gross Profit | 125.31M | 97.00M | 120.47M | 207.81M | 60.18M | -601.00K |
EBITDA | 5.91M | -13.72M | -6.87M | -43.26M | -225.96M | -341.00M |
Net Income | -45.31M | -69.41M | -51.92M | -106.01M | -244.87M | -349.87M |
Balance Sheet | ||||||
Total Assets | 310.19M | 220.67M | 241.70M | 351.83M | 525.55M | 644.14M |
Cash, Cash Equivalents and Short-Term Investments | 113.37M | 51.87M | 42.92M | 90.47M | 149.80M | 268.69M |
Total Debt | 54.15M | 47.64M | 104.18M | 99.78M | 136.05M | 126.28M |
Total Liabilities | 285.60M | 269.86M | 272.29M | 342.49M | 449.09M | 396.52M |
Stockholders Equity | 24.58M | -49.19M | -30.58M | 9.34M | 76.46M | 247.62M |
Cash Flow | ||||||
Free Cash Flow | -34.83M | -40.69M | -23.38M | -73.27M | -253.02M | -110.70M |
Operating Cash Flow | -34.81M | -40.66M | -23.38M | -73.15M | -252.97M | -110.39M |
Investing Cash Flow | 121.00K | -33.00K | 0.00 | -114.00K | 39.94M | -40.00M |
Financing Cash Flow | 106.13M | 49.66M | -25.21M | 14.60M | 133.73M | 231.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
57 Neutral | $561.01M | ― | -31.46% | ― | 6.11% | -37.79% | |
55 Neutral | $579.26M | ― | -63.53% | ― | -47.94% | 30.94% | |
54 Neutral | $558.91M | ― | -45.46% | ― | -78.26% | 15.41% | |
49 Neutral | $966.50M | ― | 91.25% | ― | -17.75% | -19.17% | |
46 Neutral | C$190.36M | -4.25 | -8.56% | 3.10% | 13.57% | -1.98% | |
39 Underperform | $482.57M | ― | ― | -25.10% | -7.06% | ||
37 Underperform | $804.97M | ― | -84.04% | ― | ― | -2.53% |
On March 19, 2025, Akebia Therapeutics announced the pricing of its public offering of 25 million shares of common stock at $2.00 per share, aiming to raise approximately $50 million before expenses. The offering, managed by Leerink Partners and Piper Sandler, is expected to close on March 21, 2025, and includes an option for underwriters to purchase an additional 3.75 million shares. Akebia anticipates net proceeds of $46.5 million, which could increase to $53.6 million if the additional shares are fully purchased, supporting its goal of achieving profitability.